These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

688 related articles for article (PubMed ID: 24378097)

  • 21. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
    J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
    Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
    Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluorine 18 fluorodeoxyglucose PET/CT volume-based indices in locally advanced non-small cell lung cancer: prediction of residual viable tumor after induction chemotherapy.
    Soussan M; Cyrta J; Pouliquen C; Chouahnia K; Orlhac F; Martinod E; Eder V; Morère JF; Buvat I
    Radiology; 2014 Sep; 272(3):875-84. PubMed ID: 24761836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
    Ohtsuka T; Nomori H; Ebihara A; Watanabe K; Kaji M; Naruke T; Suemasu K; Uno K
    Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of 18F-FDG PET/CT for detecting neck metastasis in patients with salivary gland carcinomas: preoperative planning for necessity and extent of neck dissection.
    Kim MJ; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Ann Surg Oncol; 2013 Mar; 20(3):899-905. PubMed ID: 23161114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
    Liao S; Penney BC; Zhang H; Suzuki K; Pu Y
    Acad Radiol; 2012 Jan; 19(1):69-77. PubMed ID: 22142679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic evaluations of small size lung cancers by 18F-FDG PET/CT and thin-section CT.
    Kishimoto M; Iwano S; Ito S; Kato K; Ito R; Naganawa S
    Lung Cancer; 2014 Nov; 86(2):180-4. PubMed ID: 25263854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of occult lymph node metastasis by metabolic parameters in patients with clinically N0 esophageal squamous cell carcinoma.
    Moon SH; Kim HS; Hyun SH; Choi YS; Zo JI; Shim YM; Lee KH; Kim BT; Choi JY
    J Nucl Med; 2014 May; 55(5):743-8. PubMed ID: 24700884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of circulating tumor cells and 18F-FDG PET/CT for precision diagnosis in patients with non-small cell lung cancer.
    Sun M; Lu D; Li X; Wang J; Zhang L; Yang P; Yang Y; Shen J
    Cancer Med; 2024 Sep; 13(18):e70216. PubMed ID: 39302034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
    van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
    Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sex and SUVmax: sex-dependent prognostication in early non-small cell lung cancer.
    Wainer Z; Daniels MG; Callahan J; Binns D; Hicks RJ; Antippa P; Russell PA; Alam NZ; Conron M; Solomon B; Wright GM
    J Nucl Med; 2012 Nov; 53(11):1676-85. PubMed ID: 22984219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
    Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
    J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
    Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
    Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneity in [18F]fluorodeoxyglucose positron emission tomography/computed tomography of non-small cell lung carcinoma and its relationship to metabolic parameters and pathologic staging.
    van Gómez López O; García Vicente AM; Honguero Martínez AF; Soriano Castrejón AM; Jiménez Londoño GA; Udias JM; León Atance P
    Mol Imaging; 2014; 13():. PubMed ID: 25248853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of maximum standardized uptake value on fluorodeoxyglucose positron-emission tomography in predicting lymph node involvement in patients with primary non-small cell lung cancer.
    Muto J; Hida Y; Kaga K; Ohtaka K; Okamoto S; Tamaki N; Nakada-Kubota R; Hirano S; Matsui Y
    Anticancer Res; 2014 Feb; 34(2):805-10. PubMed ID: 24511016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
    Hu WD; Wang HC; Wang YB; Cui LL; Chen XH
    Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Li Y; Wu X; Huang Y; Bian D; Jiang L
    Ann Nucl Med; 2020 May; 34(5):314-321. PubMed ID: 32088884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDG-PET and CT features of non-small cell lung cancer based on tumor type.
    Aquino SL; Halpern EF; Kuester LB; Fischman AJ
    Int J Mol Med; 2007 Mar; 19(3):495-9. PubMed ID: 17273799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Correlation between SUV of (18)F-FDG PET-CT and the expression of GLUT1, MVD and Ki67 in non-small cell lung cancer].
    Duan Y; Yu LJ; Lu PO; Wang WZ
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):764-7. PubMed ID: 19173807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.